Ronald N Marcus

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. pmc Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study
    Anita H Clayton
    Department of Psychiatry and Neurobehavioral Sciences, The University of Virginia, Charlottesville, 2955 Ivy Rd, Northridge Suite 210, Charlottesville VA 22903, USA
    BMC Res Notes 7:459. 2014
  2. ncbi Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study
    Ronald N Marcus
    Department of Research and Development, Bristol Myers Squibb, 5 Research Parkway, Wallingford, CT 06492, USA
    J Clin Psychiatry 72:1270-6. 2011
  3. ncbi Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study
    Ronald Marcus
    Bristol Myers Squibb, 5 Research Parkway, Wallingford, CT 06492, USA
    Bipolar Disord 13:133-44. 2011
  4. pmc The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913)
    Linda Hanssens
    Bristol Myers Squibb Company, Parc de l Alliance, Avenue de Finlande, 8, B 1420 Braine l Alleud, Belgium
    BMC Psychiatry 8:95. 2008
  5. ncbi Aripiprazole in the treatment of irritability in pediatric patients (aged 6-17 years) with autistic disorder: results from a 52-week, open-label study
    Ronald N Marcus
    Bristol Myers Squibb, Wallingford, Connecticut, USA
    J Child Adolesc Psychopharmacol 21:229-36. 2011
  6. ncbi Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder
    Randall Owen
    Bristol Myers Squibb, 5 Research Parkway, Wallingford, Connecticut 06492, USA
    Pediatrics 124:1533-40. 2009
  7. ncbi Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants
    Robert M Berman
    Neuroscience Global Clinical Research at Bristol Myers Squibb, Wallingford, CT 06492, USA
    CNS Spectr 14:197-206. 2009
  8. ncbi A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder
    Ronald N Marcus
    Bristol Myers Squibb, 5 Research Parkway, Wallingford, CT 06492, USA
    J Am Acad Child Adolesc Psychiatry 48:1110-9. 2009
  9. ncbi The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study
    Ronald N Marcus
    Bristol Myers Squibb, Wallingford, CT 06492, USA
    J Clin Psychopharmacol 28:156-65. 2008
  10. ncbi Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy
    James Craig Nelson
    Department of Psychiatry, University of California San Francisco, 401 Parnassus Ave, San Francisco, CA 94143, USA
    Int Clin Psychopharmacol 27:125-33. 2012

Collaborators

Detail Information

Publications13

  1. pmc Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study
    Anita H Clayton
    Department of Psychiatry and Neurobehavioral Sciences, The University of Virginia, Charlottesville, 2955 Ivy Rd, Northridge Suite 210, Charlottesville VA 22903, USA
    BMC Res Notes 7:459. 2014
    ....
  2. ncbi Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study
    Ronald N Marcus
    Department of Research and Development, Bristol Myers Squibb, 5 Research Parkway, Wallingford, CT 06492, USA
    J Clin Psychiatry 72:1270-6. 2011
    ..Evaluate the long-term safety and tolerability of aripiprazole in the treatment of irritability in pediatric subjects (6-17 years) with autistic disorder...
  3. ncbi Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study
    Ronald Marcus
    Bristol Myers Squibb, 5 Research Parkway, Wallingford, CT 06492, USA
    Bipolar Disord 13:133-44. 2011
    ....
  4. pmc The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913)
    Linda Hanssens
    Bristol Myers Squibb Company, Parc de l Alliance, Avenue de Finlande, 8, B 1420 Braine l Alleud, Belgium
    BMC Psychiatry 8:95. 2008
    ....
  5. ncbi Aripiprazole in the treatment of irritability in pediatric patients (aged 6-17 years) with autistic disorder: results from a 52-week, open-label study
    Ronald N Marcus
    Bristol Myers Squibb, Wallingford, Connecticut, USA
    J Child Adolesc Psychopharmacol 21:229-36. 2011
    ..To report the long-term efficacy of aripiprazole in the treatment of irritability in children and adolescents (ages 6-17 years) with autistic disorder...
  6. ncbi Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder
    Randall Owen
    Bristol Myers Squibb, 5 Research Parkway, Wallingford, Connecticut 06492, USA
    Pediatrics 124:1533-40. 2009
    ....
  7. ncbi Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants
    Robert M Berman
    Neuroscience Global Clinical Research at Bristol Myers Squibb, Wallingford, CT 06492, USA
    CNS Spectr 14:197-206. 2009
    ..This trial evaluated the efficacy and safety of adjunctive aripiprazole versus antidepressant monotherapy in patients with MDD and independently replicated the positive findings of two similar trials...
  8. ncbi A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder
    Ronald N Marcus
    Bristol Myers Squibb, 5 Research Parkway, Wallingford, CT 06492, USA
    J Am Acad Child Adolesc Psychiatry 48:1110-9. 2009
    ..To evaluate the short-term efficacy and safety of aripiprazole in the treatment of irritability in children and adolescents with autistic disorder...
  9. ncbi The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study
    Ronald N Marcus
    Bristol Myers Squibb, Wallingford, CT 06492, USA
    J Clin Psychopharmacol 28:156-65. 2008
    ..1%] vs adjunctive aripiprazole [3.7%]). Aripiprazole is an effective and safe adjunctive therapy as demonstrated in this short-term study for patients who are nonresponsive to standard ADT...
  10. ncbi Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy
    James Craig Nelson
    Department of Psychiatry, University of California San Francisco, 401 Parnassus Ave, San Francisco, CA 94143, USA
    Int Clin Psychopharmacol 27:125-33. 2012
    ..12%, respectively, P<0.0001). The numbers needed to treat with aripiprazole+ADT were six for response and eight for remission. Aripiprazole augmentation had a rapid and clinically meaningful effect in ADT minimal responders...
  11. ncbi The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study
    Robert M Berman
    Bristol Myers Squibb Co, Wallingford, Conn 06492, USA
    J Clin Psychiatry 68:843-53. 2007
    ....
  12. pmc Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder
    Robert M Berman
    Neuroscience Global Clinical Research Bristol Myers Squibb, Wallingford, CT, USA
    Neuropsychiatr Dis Treat 7:303-12. 2011
    ..Effective management of major depressive disorder often includes the long-term use of multiple medications, and the longer-term utility and safety of adjunctive aripiprazole has not been evaluated in a controlled setting...
  13. ncbi Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo
    Gilbert J L'italien
    Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492, USA
    J Clin Psychiatry 68:1510-6. 2007
    ....